The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression.
about
The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
The ATR inhibitor AZD6738 syne ...... tal adenocarcinoma regression.
@en
The ATR inhibitor AZD6738 syne ...... tal adenocarcinoma regression.
@nl
type
label
The ATR inhibitor AZD6738 syne ...... tal adenocarcinoma regression.
@en
The ATR inhibitor AZD6738 syne ...... tal adenocarcinoma regression.
@nl
prefLabel
The ATR inhibitor AZD6738 syne ...... tal adenocarcinoma regression.
@en
The ATR inhibitor AZD6738 syne ...... tal adenocarcinoma regression.
@nl
P2093
P2860
P50
P1476
The ATR Inhibitor AZD6738 Syne ...... ctal Adenocarcinoma Regression
@en
P2093
Chiara Fornari
Duncan I Jodrell
James W T Yates
Timothy Isaac Johnson
P2860
P304
P356
10.1158/1535-7163.MCT-18-0010
P577
2018-06-11T00:00:00Z